Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Sarcoma, Alveolar Soft Part 1Papillomavirus Infections 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Gynecologic Cancer 1Carcinoma in Situ 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

atezolizumab 3Specimen Handling 2spartalizumab 1selinexor 1sargramostim 1pembrolizumab 1pazopanib 1fludarabine 1cediranib 1cabozantinib 1atropine sulfate-diphenoxylate hydrochloride drug combination 1anlotinib 1Zoledronic Acid 1Warfarin 1Vitamin B 6 1Thyroxine 1Tablets 1Sunitinib 1Rosuvastatin Calcium 1Radiotherapy 1Radiation 1Pyridoxine 1Promethazine 1Prochlorperazine 1Petrolatum 1Midazolam 1Lorazepam 1Loperamide 1Immunoglobulin G 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × Prochlorperazine × 1 year × Clear all
NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
34 enrolled 22 charts
Sarcoma

Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡